Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $550,568.16 in Stock

by · The Markets Daily

Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) insider Joana Goncalves sold 7,947 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the sale, the insider directly owned 32,718 shares of the company’s stock, valued at $2,266,703.04. The trade was a 19.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Joana Goncalves also recently made the following trade(s):

  • On Friday, May 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $61.85, for a total value of $432,950.00.
  • On Wednesday, April 15th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $66.12, for a total value of $462,840.00.

Oruka Therapeutics Trading Up 4.7%

ORKA stock opened at $70.88 on Thursday. The company has a market capitalization of $4.27 billion, a P/E ratio of -36.54 and a beta of -0.26. Oruka Therapeutics, Inc. has a twelve month low of $10.77 and a twelve month high of $91.00. The business has a 50 day simple moving average of $64.29 and a 200-day simple moving average of $44.86.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. Research analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Avidity Partners Management LP lifted its holdings in Oruka Therapeutics by 15.1% in the first quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after acquiring an additional 100,000 shares during the period. Glenmede Trust Co. NA lifted its holdings in Oruka Therapeutics by 11.7% in the first quarter. Glenmede Trust Co. NA now owns 21,772 shares of the company’s stock valued at $1,068,000 after acquiring an additional 2,287 shares during the period. Remedium Capital Partners LLC lifted its holdings in Oruka Therapeutics by 0.9% in the first quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after acquiring an additional 13,247 shares during the period. Royal Bank of Canada lifted its holdings in Oruka Therapeutics by 178.5% in the first quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after acquiring an additional 2,033 shares during the period. Finally, Rock Springs Capital Management LP acquired a new stake in Oruka Therapeutics in the first quarter valued at $202,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Wall Street Analyst Weigh In

ORKA has been the subject of several recent research reports. Wedbush set a $165.00 price target on Oruka Therapeutics in a report on Monday, April 27th. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a report on Wednesday, June 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Barclays increased their price target on Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a report on Monday, April 27th. Finally, UBS Group increased their price target on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Oruka Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.

View Our Latest Research Report on Oruka Therapeutics

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Recommended Stories